Characterizing Effects of Erenumab on Patients with Menstrually-Related Migraines
Brief description of study
A retrospective observational study identifying the effects of CGRP antagonist, erenumab-aooe (Aimovig), on migraine in female patients between the age of 18 to 55. They will be asked to complete a questionnaire to determine if these agents are an effective treatment for menstrually-related migraines.
Clinical Study Identifier: s19-01534
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
